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Introduction: Recent studies have revealed that lung inflammation mediated by CD4+ T cells may contribute to
the pathogenesis of acute respiratory distress syndrome (ARDS). The imbalance between CD4 + CD25 + Foxp3 +
regulatory T (Treg) cells and T helper (Th)17 cells has been found in a number of different inflammation and
autoimmune diseases, while the role of the Th17/Treg balance in ARDS remains largely unknown. The aim of
this study was to investigate the Th17/Treg pattern and its impact on disease severity and outcomes in patients
with ARDS.
Methods: This prospective, observational study enrolled 79 patients who fulfilled the Berlin definition of ARDS
and 26 age- and sex-matched healthy controls. Circulation Th17 and Treg cell frequencies were analyzed by flow
cytometry, and the expressions of Th17- and Treg-related cytokines in serum were measured by enzyme-linked
immunosorbent assay (ELISA). Acute Physiologic and Chronic Health Evaluation (APACHE) II score, Sequential Organ
Failure Assessment (SOFA) score, and the Lung Injury Score were also calculated at enrollment.
Results: Within 24 hours after the onset of ARDS, the changes of peripheral circulating Th17 and Treg cell
frequencies gradually increased from mild to severe ARDS. Th17/Treg ratio was positively correlated with APACHE II
score, SOFA score, and Lung Injury Score, while negatively correlated with PaO2/FiO2. The areas under the receiver
operating characteristic (AUC) curves of Th17/Treg ratio for predicting 28-day mortality in ARDS patients was higher
than that of APACHE II score, SOFA score, Lung injury score, as well as PaO2/FiO2. Using a Th17/Treg ratio cutoff
value of >0.79 to determine 28-day mortality, the sensitivity was 87.5% with 68.1% specificity. Multivariate logistic
regression showed Th17/Treg ratio >0.79 (odds ratio = 8.68, P = 0.002) was the independent predictor for 28-day
mortality in patients with ARDS. Finally, cumulative survival rates at 28-day follow-up also differed significantly
between patients with Th17/Treg ratio >0.79 and ≤0.79 (P <0.001).
Conclusions: The Th17/Treg imbalance favoring a Th17 shift represents a potential therapeutic target to alleviate
lung injury and a novel risk indicator in patients with early ARDS.Introduction
Acute respiratory distress syndrome (ARDS) is a life-
threatening clinical syndrome of rapid-onset pulmonary
failure with high morbidity and mortality in critically ill
patients [1,2]. Despite decades of intense research, the
pathogenesis leading to this devastating disease remains
poorly defined. However, clinical and animal studies
have shown that activation of multiple inflammatory* Correspondence: jinzc57@163.com; jxuzh135@163.com
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unless otherwise stated.cells and release of inflammatory mediators play an im-
portant role in the development and outcome of ARDS
[1]. Among those cells, immune cells including neutro-
phils [3], macrophages [4] and dendritic cells [5] in-
volved in this process have been studied extensively.
Most recently, the involvement of lymphocytes, espe-
cially CD4+ T cells, in the pathogenesis of ARDS has be-
come an active topic of research [6-12].
CD4 + CD25 + Foxp3 + regulatory T (Treg) cells have
an anti-inflammatory role mainly by contact-dependent
suppression or releasing cytokines, IL-10 and transform-
ing growth factor (TGF)-β1 on other immune cells, in-
cluding CD4+ and CD8+ T cells, B cells, natural killeris an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tions have revealed that reduced generation or deficient
function of Treg cells, which is associated with disease
severity and activity, has been found in patients with
various inflammation and autoimmune diseases [13]. In
mice and patients with acute lung injury (ALI), the al-
veolar recruitment of Treg cells, specifically mediated by
leukotriene B4 (LTB4)-leukotriene B4 Receptor (BLT1)
pathway [10], contribute to the resolution of lung in-
flammation [7], particularly in the resolution of ALI
fibroproliferation [9]. However, data from a recent obser-
vational clinical study showed that an increased Treg cell
ratio in bronchoalveolar lavage fluid (BALF) obtained
from ARDS patients on admission is an independent risk
factor for 30-day mortality [8]. Therefore, the precise
role of Treg cells on ARDS and its resolution remains to
be explored.
In contrast to Treg cells, a more recently discovered
effector subset of CD4+ T cells, Th17 cells play a potent
proinflammatory role in the immune system through
producing the signature cytokines IL-17 and to a lesser
extent other inflammatory mediators including IL-6,
TNF-α, granulocyte-macrophage colonystimulating fac-
tor [13]. In addition to their effector function in defense
against extracellular pathogens, T helper (Th)17 cells
can promote many autoimmune inflammatory condi-
tions including several lung diseases (asthma [14], tuber-
culosis [15], lung cancer [16], and chronic obstructive
pulmonary disease [17]), unless they are efficiently con-
trolled by regulatory cells [13]. Remarkably, Th17 devel-
opment relies on the key cytokine TGF-β1, which is also
linked to Treg cell development and function, indicating
that Th17 and Treg not only exert opposite functions in
the immune response but also share reciprocal develop-
ment pathways. Moreover, under certain inflammatory
environments, differentiated Treg cells have a tendency
to be reprogrammed and converted into Th17 cells
[13,18]. Thus, it is reasonable to hypothesize that the
fine balance between Th17 and Treg is crucial for main-
tenance of immune homeostasis.
The imbalance of Th17/Treg has also been found in a
number of different inflammation and autoimmune
diseases [13]. Although the role of Th17 cells in the de-
velopment and progress of ARDS is currently unclear,
IL-17, the cytokine preferentially produced by Th17
cells, has been widely investigated in lung diseases in-
cluding ARDS [19]. Furthermore, Th17 cells have been
implicated in other lung diseases in animal experimenta-
tion and clinical studies [20]. In addition to Th17 cells
found in the BALF fluid of patients with respiratory
diseases, two studies have shown that losartan and alanyl-
glutamine may protect mice from lipopolysaccharide-
induced lung injury by suppressing Th17 immune
responses and modulating the Th17/Treg balance infavor of Treg cells, respectively [5,12]. Therefore, we
hypothesize that the imbalance of Th17/Treg might
exist and play a role in the pathogenesis of inflamma-
tion in ARDS. To test this hypothesis, we investigated
the distribution of Th17 cells in relation to Treg cells
in ARDS patients, and evaluated how the imbalance of
Th17/Treg and their related cytokines correlate with
the disease severity.Materials and methods
Subjects and protocol
This prospective, observational study was conducted in
the 30-bed, level-3 multi-disciplinary, adult ICU of the
Affiliated People’s Hospital, Jiangsu University. Between
June 2012 and January 2014, consecutive patients ad-
mitted to our ICU were considered eligible if they met
the Berlin definition of ARDS [2]. Patients were classi-
fied according to the arterial partial pressure of oxy-
gen/inspired oxygen fraction (PaO2/FiO2) ratio as mild
(200 mmHg < PaO2/FiO2 ≤ 300 mmHg, n = 24), moder-
ate (100 mmHg < PaO2/FiO2 ≤ 200 mmHg, n = 28), and
severe (PaO2/FiO2 ≤ 100 mmHg, n = 27). The exclu-
sion criteria were as follows: age <18 years, known
history of cancer, end-stage liver or renal disease, and
chronic immune-mediated disorders. At the time of
sample collection, none of the patients had received any
corticosteroids, or other non-steroid anti-inflammatory
drugs. In addition, we also excluded the patients who died
within 24 h of receiving a diagnosis of ARDS.
Finally, after excluding 12 patients who failed to meet
the inclusion criteria and 7 patients who were lost to fol-
low up, 79 patients were enrolled and were also catego-
rized as survivors (n = 47) and non-survivors (n = 32)
according to clinical outcome within 28 days of follow
up. Twenty-six age- and sex-matched healthy volunteers
without a history of any chronic disease served as con-
trols. This study was approved by the Ethics Committee
of the Affiliated People’s Hospital, Jiangsu University. In-
formed consent from all of the subjects or their relatives
was obtained before enrollment.Data collection and outcome
After enrollment, demographics and baseline charac-
teristics such as age, sex, body mass index (BMI), risk
factors for ARDS, severity of illness at ICU admission
(acute physiologic and chronic health evaluation
(APACHE) II score) [21], sequential organ failure as-
sessment (SOFA) score [22], and the lung injury score
[23] were also calculated after ICU admission. All pa-
tients were followed up for 28 days. The main out-
comes were mortality at discharge from ICU and from
hospital at 28 days.
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Within 24 h after diagnosis of ARDS, peripheral whole
blood samples were collected in tubes containing hep-
arin or ethylene diamine tetraacetate acid (EDTA), and
serum was obtained after centrifugation and stored at
−80°C until used. White blood cell count, C-reactive
protein (CPR) and procalcitonin (PCT) were immedi-
ately measured in the clinical chemistry laboratory of
the Affiliated People’s Hospital. The serum levels of TGF-β1,
IL-6, IL-10, and IL-17 (all from R&D Systems, Minneapolis,
MN) were determined by enzyme-linked immunosorbent
assay (ELISA), following the manufacturer’s instructions.
Flow cytometric analysis
Peripheral blood mononuclear cells (PBMCs) were
freshly isolated by Ficoll density gradient centrifugation
(Pharmacia, Uppsala, Sweden). The isolated PBMCs were
washed twice with PBS) and resuspended at 1 × 106 cells/
mL in complete culture medium (RPMI 1640 supple-
mented with 1% penicillin/streptomycin, 2 mM L-glutam-
ine, and 10% heat-inactivated fetal bovine serum; Gibco
BRL, Gaithersburg, MD, USA).
For Th17 cells analysis, IL-17-producing CD3+ lym-
phocytes were detected as described previously [24].
PBMCs were stimulated for 4 h with 2 μ/mL leukocyte
activation cocktail (BD Pharmingen™, USA) at 37°C and
5% CO2. Upon harvest, cells were then washed twice
using PBS, and surface-stained with APC-conjugated anti-
CD8 (BD Pharmingen™, USA) and PerCP-conjugated anti-
CD3 (BD Pharmingen™, USA) for 20 minutes at room
temperature in the dark. Following surface staining, cells
were incubated with PE-conjugated anti-IL-17A (BD Phar-
mingen™, USA) after fixation and permeabilization using
the IntraPrep Permeabilization Reagent (Beckman Coulter
Inc., France).
For the analysis of Treg cells, a human regulatory T-cell
staining kit (BD Pharmingen™, USA) was used to measure
CD4 + CD25 + Foxp3+ cells as Treg cells according to the
manufacturer’s protocol. Briefly, PBMCs was incubated
with a cocktail of fluorescein isothiocyanate-conjugated
anti-CD4 and APC-conjugated anti-CD25 for 30 minutes
at 4°C. After fixation and permeabilization, the cells were
blocked by normal rat serum and stained using PE-
conjugated anti-Foxp3 for 45 minutes at 4°C.
The flow cytometry analyses were performed on a
FACSCalibur flow cytometer (BD biosciences, San Jose,
CA, USA) equipped with CellQuest software (BD biosci-
ences). Isotype controls were conducted to ensure anti-
body specificity.
Statistical analysis
All analyses were done using SPSS, version 20.0 (IBM
Corp., Armonk, NY, USA) and MedCalc version 11.0
(MedCalc Software, Inc, Mariakerke, Belgium). Continuousvariables were reported as mean ± SD or as median
(IQR) after testing their normal distribution using the
Kolmogorov-Smirnov test.
For two-group comparisons, the independent samples
t-test was used for normally distributed data, and the
Mann-Whitney test was used for non-normally distrib-
uted data. For the comparison of multi-group, one-way
analysis of variance and the Kruskal-Wallis test was used
to analyze normally and non-normally distributed data,
respectively, and P-values were adjusted with the Bonfer-
roni correction for multiple comparisons. Categorical
data are summarized using number (percentage), and
were compared using the chi-square or Fisher’s exact
test. Spearman’s rank correlation was applied to deter-
mine the correlation between variables.
The area under the receiver operating characteristic
(ROC) curve was calculated to evaluate the diagnostic
and prognostic value of the tested parameters. The
cutoff points were calculated by acquiring the best
Youden index (sensitivity + specificity − 1). Kaplan-
Meier plots and the log-rank test were used to com-
pare survival in several groups. To determine the inde-
pendent predictors of 28-day mortality, binary logistic
regression analysis was performed as stepwise regres-
sion (entering a variable if P was <0.05, removing a
variable if P was >0.10) for variables with a P-value of
<0.05. Results were expressed as the odds ratio (OR),
P-value and 95% CI.
All tests were two-tailed, and a value of P <0.05
was considered statistically significant. In addition,
P <0.008 (after Bonferroni correction) was used for
multiple comparisons.
Results
Baseline characteristics and patient outcome
Between June 2012 and January 2014, a total of 79 pa-
tients who fulfilled the Berlin definition of ARDS and 26
healthy volunteers were included in this study. Tables 1
and 2 show the characteristics at enrollment and out-
comes of the study population. No significant differences
were found in age, gender and body mass index (BMI)
among the four groups (mild, moderate, severe ARDS,
and control groups). Pneumonia, sepsis and trauma were
the most common etiology of ARDS. As shown in
Tables 1 and 2, severity of critical illness on the day of
enrollment, measured by the APACHE II score (P
<0.001), SOFA score (P <0.001), lung injury score (P
<0.001) and PaO2/FiO2 (P <0.001), worsened from
mild to severe ARDS. The 28-day mortality was 40.5%
(32/79) in patients with ARDS. Compared with survi-
vors, non-survivors had significantly higher APACHE
II and SOFA scores. In addition, survivors had higher
PaO2/FiO2 and lower lung injury score than non-
survivors.
Table 1 Baseline characteristics of the population enrolled in the study
Variables Control Acute respiratory distress syndrome ¶P-value
Total Mild Moderate Severe
Number 26 79 24 28 27
Age, years 54.00 ± 13.77 55.03 ± 14.42 55.17 ± 15.45 53.36 ± 13.34 57.63 ± 15.57 0.714
Gender, male/female, n 14/12 44/35 13/11 15/13 16/11 0.971
BMI, kg/m2 22.44 ± 3.53 24.03 ± 4.13 24.72 ± 4.98 24.67 ± 3.84 24.26 ± 3.93 0.150
Cause of ARDS
Pneumonia 25 6 9 10
Non-pulmonary sepsis 19 4 8 7
Trauma 23 9 6 8
Aspiration 5 2 2 1
Multiple transfusions 4 2 2
Others 3 1 1 1
APACHE II score 22 (20 to 26) 20 (18 to 22) 23 (21 to 26)* 25 (22 to 27)* <0.001
SOFA score 11.0 (10.0 to 13.0) 9.5 (7.0 to 11.8) 11.0 (10.0 to 13.0)* 12.0 (11.0 to 13.0)* <0.001
Lung injury score 2.3 (2.1 to 2.8) 2.0 (1.9 to 2.1) 2.3 (2.1 to 2.5)* 2.9 (2.7 to 3.2)*# <0.001
PaO2/FiO2 (mmHg) 138 (76 to 222) 258 (223 to 273) 139 (120 to 158)* 67 (59 to 79)*
# <0.001
CRP, mg/L 4.97 (3.83 to 6.12) 135.84 (116.83 to 156.79) 116.69 (104.17 to 133.33) 130.97 (123.40 to 154.45) 156.85 (143.59 to 185.36)* <0.001
PCT, ng/mL 0.04 (0.02 to 0.06) 1.56 (1.24 to 1.83) 1.24 (1.05 to 136) 1.47 (1.27 to 1.66) 2.04 (1.62 to 2.61)*# <0.001
Leukocytes, 109/L 6.8 (5.6 to 8.2) 12.9 (11.2 to 14.8) 11.8 (10.5 to 12.8) 12.4 (10.7 to 13.7) 15.3 (13.6 to 17.6)*# <0.001
Monocytes, 109/L 0.58 (0.46 to 0.69) 1.05 (0.92 to 1.23) 0.95 (0.84 to 1.13) 1.04 (0.88 to 1.23) 1.12 (1.04 to 1.1.26)* <0.001
Lymphocytes, 109/L 3.09 (2.80 to 3.52) 5.35 (4.25 to 6.47) 4.24 (3.93 to 4.96) 5.24 (4.19 to 6.06)* 6.72 (5.69 to 7.45)*# <0.001
Th17 cells, % of CD4+ 0.71 (0.59 to 0.94) 4.27 (3.67 to 6.02) 3.54 (3.17 to 3.94) 4.16 (3.96 to 4.54)* 6.42 (5.96 to 6.91)*# <0.001
Treg cells, % of CD4+ 3.11 (2.70 to 3.44) 5.37 (4.98 to 6.07) 4.82 (4.50 to 5.18) 5.46 (5.25 to 5.81)* 6.18 (5.82 to 6.57)*# <0.001
Th17/Treg ratio 0.25 ± 0.09 0.86 ± 0.20 0.74 ± 0.12 0.77 ± 0.10 1.01 ± 0.18*# <0.001
IL-6, pg/mL 11.70 ± 1.31 758.33 ± 70.03 721.53 ± 54.43 763.62 ± 76.96* 785.56 ± 62.36* <0.001
IL-17, pg/mL 20.27 ± 4.12 199.59 ± 68.12 139.42 ± 25.51 204.75 ± 37.64* 247.72 ± 78.08*# <0.001
IL-10, pg/mL 123.04 ± 20.53 131.19 ± 19.94 137.8 ± 19.17 132.49 ± 20.14 124.17 ± 18.87 0.029
TGF-β1, pg/mL 193.48 ± 46.48 209.92 ± 51.00 219.30 ± 61.84 200.30 ± 41.77 211.55 ± 49.25 0.264
28-day mortality, n, % 32 (40.5%) 7 (29.17%) 12 (42.86%) 13 (48.15%)
Quantitative data with a normal distribution are presented as mean ± SD. Quantitative data with a non-normal distribution are presented as median (IQR). Qualitative data are presented as number (%). ¶P-value for the
four groups (mild, moderate, severe ARDS, and control groups); *P <0.01 versus mild ARDS; #P <0.01 versus moderate ARDS. BMI, body mass index; APACHE, acute physiologic and chronic health evaluation; SOFA,









Table 2 Comparison of clinical characteristics of patients with acute respiratory distress syndrome (ARDS) according to
survival
Variables Non-survivors (n = 32) Survivors (n = 47) P-value
Age, years 53.38 ± 13.80 56.72 ± 15.27 0.323
Gender, male/female, n 17/15 26/21 0.848
BMI, kg/m2 24.34 ± 4.12 24.69 ± 4.29 0.716
APACH II score 26 (22 to 27) 21 (19 to 23) <0.001
SOFA score 12 (11 to 13) 10 (9 to 12) <0.001
Lung injury score 2.6 (2.2 to 3.1) 2.1 (2.0 to 2.7) 0.002
PaO2/FiO2, mmHg 111 (67 to 183) 157 (84 to 231) 0.037
CRP, mg/L 138.59 (123.40 to 165.47) 135.64 (116.53 to 156.76) 0.413
PCT, ng/mL 1.64 (1.33 to 2.05) 1.38 (1.07 to 1.67) 0.031
Leukocytes, 109/L 13.2 (11.5 to 15.8) 12.7 (10.8 to 14.5) 0.507
Monocytes, 109/L 1.07 (0.99 to 1.28) 1.04 (0.88 to 1.18) 0.124
Lymphocytes, 109/L 5.76 (4.80 to 6.61) 5.10 (4.16 to 6.21) 0.044
Th17 cells, % of CD4+ 4.84 (4.25 to 6.76) 4.01 (3.56 to 5.34) <0.001
Treg cells, % of CD4+ 5.33 (4.98 to 5.94) 5.46 (4.98 to 6.12) 0.583
Th17/Treg ratio 0.98 ± 0.20 0.78 ± 0.15 <0.001
IL-6, pg/mL 790.68 ± 66.95 736.30 ± 63.80 <0.001
IL-17, pg/mL 229.09 ± 77.18 179.50 ± 53.25 0.003
IL-10, pg/mL 128.48 ± 21.87 133.04 ± 18.53 0.321
TGF-β, pg/mL 216.81 ± 55.44 205.23 ± 47.80 0.325
Quantitative data with a normal distribution are presented as mean ± SD. Quantitative data with a non-normal distribution are presented as median (IQR). BMI,
body mass index; APACHE, acute physiologic and chronic health evaluation; SOFA, sequential organ failure assessment; CRP, C-reactive protein; PCT, procalcitonin.
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and Treg cells and their associated cytokines in ARDS
patients
The changes in inflammatory biomarkers, Th17 and
Treg cell frequencies and their associated cytokine levels
in each group are shown in Tables 1 and 2. Compared to
the healthy control group, the levels of CRP and PCT, and
the counts of leukocytes, monocytes, and lymphocytes
were markedly elevated in ARDS patients (P <0.001)
(Table 1). PCT levels and leukocyte counts were higher in
patients with severe ARDS than in patients with mild or
moderate ARDS, and patients with severe ARDS also had
higher CPR levels and monocytes count as compared to
patients with mild ARDS (P <0.01) (Table 1). Interestingly,
the lymphocyte count increased as the severity of
ARDS increased from mild to severe (P <0.01) (Table 1).
Furthermore, non-survivors had higher PCT levels and
lymphocyte counts than did survivors, but the CRP
levels and leukocyte and monocyte counts were similar
in the two groups (Table 2).
As shown in Table 1, the frequencies of Th17 and
Treg cells were evidently increased in the peripheral
blood of ARDS patients than those in the control
group (P <0.001). Moreover, the changes in Th17 and
Treg cell frequencies progressively increased withARDS severity from mild to moderate and severe
ARDS (P <0.01). However, although the frequencies of
Th17 cells in non-survivors were higher as compared
to those in survivors, there was no significant differ-
ence between two groups in frequencies of Treg cells
(Table 2). Given the changes in these two types of
immune cells, we used the Th17/Treg ratio to describe
their relationship to further investigate their functions
and differentiation. The Th17/Treg ratio was signifi-
cantly higher in patients with ARDS when compared
with the control group (P <0.001, Table 1). Further-
more, patients with severe ARDS had a higher Th17/
Treg ratio than patients with mild and moderate ARDS
(P <0.01) (Table 1). In non-survivors, a highly significant
Th17/Treg ratio was also found in favor of a proinflamma-
tory Th17-response (P <0.001) (Table 2).
Th17-related cytokines (IL-6, IL-17) and Treg-related
cytokines (IL-10, TGF-β1) were detected by means of
ELISA (Tables 1 and 2). IL-6 and IL-17 were significantly
higher compared with those in the control group
(P <0.001) (Table 1), and both these cytokines were as-
sociated with the severity or progression of ARDS, as
non-survivors had significantly higher IL-6 and IL-17
levels (P <0.001, P = 0.003, respectively) (Table 2).
While IL-10 levels was increased in ARDS patients
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(Table 1), there was no significant difference in the TGF-β1
levels among all groups (P = 0.264) (Table 1). In addition,
levels of both IL-10 and TGF-β1 were similar between sur-
vivors and non-survivors (P = 0.321, P = 0.325, respectively)
(Table 2).
Correlation of Th17/Treg ratio with disease severity and
outcome
Spearman correlation analysis of Th17/Treg ratio with
APACHE II score, SOFA score, lung injury score, and
PaO2/FiO2 in ARDS patients are displayed in Figure 1.
For all patients with ARDS, the significantly positive and
moderate correlations were found between Th17/Treg
ratio and APACHE II score (r = 0.499, P <0.001), SOFA
score (r = 0.363, P = 0.001), Lung injury score (r = 0.699,
P <0.001), respectively. Furthermore, we noticed a nega-
tive and moderate correlation between the Th17/Treg
ratio and PaO2/FiO2 (r = −0.670, P <0.001).
The ROC curves for Th17/Treg ratio, APACHE II
score, SOFA score, lung injury score, PaO2/FiO2 and
Th17/Treg ratio in combination with APACHE II score
for predicting 28-day mortality in ARDS patients are
shown in Figure 2. The area under the ROC curve
(AUC) of Th17/Treg ratio for predicting 28-day mortal-
ity in ARDS patients was 0.824 (95% CI 0.722 to 0.901),
higher than that for the APACHE II score (0.791, 95%Figure 1 Relationship between ratio of Th17/Treg cells and acute phy
organ failure assessment (SOFA) or lung injury score, or arterial parti
patients with acute respiratory distress syndrome (ARDS). Spearman r
cells was positively correlated with APACHE II score (A), SOFA score (B), an
FiO2 (D) in ARDS patients.CI 0.684 to 0.874), but this was not statistically signifi-
cant (P = 0.558). Compared to the Th17/Treg ratio, the
AUC for the lung injury score (0.704, 95% CI 0.590 to
0.801) was significantly lower (P = 0.011); the AUC for
the SOFA score was also lower (0.749, 95% CI 0.639 to
0.840), but this difference did not reach statistical signifi-
cance (P = 0.257). Moreover, the AUC for PaO2/FiO2 for
28-day mortality was 0.639 (95% CI 0.523 to 0.744) com-
pared to the AUC for the Th17/Treg ratio, APACHE II
score, SOFA score, and lung injury score (P = 0.0001,
0.01, 0.132, and 0.063, respectively). The AUC for the
Th17/Treg ratio in combination with the APACHE II
score was 0.872 (95% CI 0.790 to 0.954), which was sig-
nificantly higher than that for the APACHE II score
alone for predicting 28-day mortality (P = 0.034), and
there was no difference for the combination of the
Th17/Treg ratio and APACHE II score compared with
the Th17/Treg ratio alone (P = 0.171).
Using a Th17/Treg ratio cutoff value of >0.79 for pre-
dicting 28-day mortality in patients with ARDS, the sen-
sitivity and specificity was 87.5% and 68.1%, respectively,
and the positive and negative likelihood ratios were 2.74
and 0.18.
Predictors for 28-day mortality in patients with ARDS
Table 3 shows that the Th17/Treg ratio (OR = 8.68,
P = 0.002), APACHE II score (OR = 1.32, P = 0.007), andsiology and chronic health evaluation (APACHE) II, sequential
al pressure of oxygen/inspired oxygen fraction (PaO2/FiO2) in
ank correlation was tested between variables. The ratio of Th17/Treg
d lung injury score (C), while it was negatively correlated with PaO2/
Figure 2 Receiver operating characteristic (ROC) curves for the Th17/Treg ratio, acute physiology and chronic health evaluation
(APACHE) II, sequential organ failure assessment (SOFA) and lung injury scores, arterial partial pressure of oxygen/inspired oxygen
fraction (PaO2/FiO2), and Th17/Treg ratio in combination with APACHE II score for predicting 28-day mortality in patients with acute
respiratory distress syndrome (ARDS). The area under the curve (AUC) demonstrates that the Th17/Treg ratio measures 0.824 (95% CI 0.722 to
0.901), the APACHE II score measures 0.791 (95% CI 0.684 to 0.874), the SOFA score measures 0.749 (95% CI 0.639 to 0.840), the lung injury score
measures 0.704 (95% CI 0.590 to 0.801), PaO2/FiO2 measures 0.639 (95% CI 0.523 to 0.744) and the Th17/Treg ratio in combination with the
APACHE II score measures 0.872 (95% CI 0.790 to 0.954).
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predictors of 28-day mortality in patients with ARDS.
Moreover, ARDS patients with a Th17/Treg ratio >0.79
had higher 28-day mortality (P <0.001, Figure 3).
Discussion
It is generally believed that inflammatory cells and their
associated mediators are mandatory in the pathologicalprocess of ARDS. Over the past few decades, despite ex-
tensive studies on these cells and mediators in both
humans and mice, the pathogenesis of ARDS remains
poorly understood [1,3,4,25]. Recently, it has been sug-
gested that T lymphocytes, especially CD4+ T cells, con-
tribute to the progress of autoimmune and inflammation
diseases, including ARDS [1,5-12]. In this study, we dem-
onstrated that the Th17/Treg balance in the peripheral
Table 3 Logistic regression analysis of mortality prediction for patients with acute respiratory distress syndrome
(ARDS)
Variables Univariate analysis Multivariate analysis
Odds ratio (95% CI) P-value Odds ratio (95% CI) P-value
APACHE II score, per point 1.42 (1.19, 1.68) <0.001 1.32 (1.08, 1.62) 0.007
SOFA score, per point 1.62 (1.22, 2.15) 0.001 1.49 (1.04, 2.15) 0.030
Lung injury score, >2.1 5.18 (1.70, 15.74) 0.004
PaO2/FiO2, per log10 (mmHg) 0.14 (0.02, 1.00) 0.051
PCT, per log10 (ng/mL) 2.38 (0.98, 5.78) 0.056
Lymphocytes, >5.24 × 109/L 2.97 (1.15, 7.64) 0.024
Th17 cells, >4.12% of CD4+ 8.70 (2.84, 26.69) <0.001
IL-6, >794.63 pg/mL 5.53 (1.97, 15.48) 0.001
IL-17, >188.56 pg/mL 3.88 (1.49, 10.09) 0.005
Th17/Treg ratio, >0.79 14.93 (4.44, 50.28) <0.001 8.68 (2.25, 33.54) 0.002
APACHE, acute physiologic and chronic health evaluation; SOFA, sequential organ failure assessment; PCT, procalcitonin.
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response compared to the control group. Moreover, the
circulating Th17/Treg ratio of non-survivors was signifi-
cantly higher than that of survivors. The ratio of Th17/
Treg cells was also closely related to the severity of illness
and 28-day mortality in ARDS patients. Thus, the skewing
of the Th17/Treg ratio may contribute to the pathogenesis
of ARDS.
Prior studies have shown that Treg cells, as important
regulators of immune response mainly though cell-to-
cell contact and secretion of the inhibitory cytokines IL-
10 and TGF-β1, infiltrate the lung and may be involved
in pathogenesis of ARDS. D’Alessio et al. showed for the
first time that Treg cells accumulate in the BALF of
mice and patients with ALI and contribute to the reso-
lution of ALI by inducing TGF-β1 and neutrophil apop-
tosis [7]. They further showed that Treg cells reduce
ALI fibroproliferation through control of fibrocyte re-
cruitment to the lung after lipopolysaccharide-induced
injury [9]. Moreover, Wang et al. demonstrated that the
well-known proinflammatory LTB4-BLT1 pathway mayFigure 3 Kaplan-Meier survival curve for patients with ARDS
using the cutoff value of Th17/Treg ratio based on receiver
operating characteristic (ROC) analysis. Log-rank test (P <0.001).contribute to the resolution of ALI by mediating the al-
veolar recruitment of Treg cells [10]. In addition to these
studies that were mainly performed in mice with ALI, in
a recent observational clinical study the researchers re-
ported that an increased ratio of CD4 + CD25 + Foxp3 +
Treg cells to all CD4+ cells in BALF obtained from
ARDS patients on admission is an independent risk fac-
tor for 30-day mortality, although the ratio of Treg to all
CD4+ cells in the blood was not associated with 30-day
mortality and did not differ between patients with ARDS
and controls [8]. However, in the current study, the Treg
cell percentage in peripheral blood was significantly
higher in patients with ARDS than in the control group.
Furthermore, the changes in Treg cell frequencies pro-
gressively increased with ARDS severity from mild to
moderate and severe ARDS. The frequency of Treg cells
in survivors tended to be higher, although this trend did
not reach statistical significance. The difference may be
largely due to the different study groups. Adamzik et al.
only studied ARDS cases caused by community-acquired
pneumonia, whereas we recruited a mixed population
including patients with pulmonary and extrapulmonary
ARDS. Indeed, ARDS is a heterogeneous syndrome that
can occur as a result of multiple insults and diseases. It
is noteworthy that the differences between pulmonary
and extrapulmonary ARDS may exist not only in morph-
ology and respiratory physiology but also in response to
therapeutic interventions, despite the fact that a com-
mon end state may be present [26].
As a more recently discovered effector subset of CD4+
T cells, Th17 cells play a key role in defense against
extracellular pathogens, and promote many autoimmune
inflammatory conditions [13]. Although the role of Th17
cells has been investigated in several lung diseases, such
as asthma [14], tuberculosis [15], lung cancer [16], and
chronic obstructive pulmonary disease [17], there are
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ARDS patients. In our study, we found that ARDS pa-
tients exhibited a significant increase in the frequency of
Th17 cells and their signature cytokine, IL-17, compared
to the control group. Moreover, a similar significant dif-
ference was observed between survivors and non-
survivors. These results suggest a potential role for cir-
culating Th17 cells to reflect the severity of lung injury.
Th17 cells and Treg cells not only share reciprocal de-
velopment pathways but also are mutually opposite in
function. Naïve CD4+ T cells differentiate into distinct
functional subsets account to the local cytokine environ-
ment. Moreover, under certain inflammatory milieu,
differentiated Treg cells can be converted into Th17
cells [13,18]. TGF-β alone induces the differentiation
into Treg cells, but in an IL-1- and/or IL-6-rich in-
flammatory milieu, the Th17 generation is enhanced
while the Treg cells are inhibited [18]. The elevated
levels of IL-6 found in ARDS patients and non-survivors
compared to the control group and survivors, respect-
ively, are in line with the mechanism by which Th17
cells are promoted while Treg cells are suppressed.
The Th17/Treg balance toward Th17 cells might enhance
the local accumulation of inflammatory mediators,
and ultimately create a pathogenic proinflammatory
loop to amplify proinflammatory responses in patients
with ARDS.
The balance between Th17 and Treg cells has been
suggested as a new paradigm for a number of different
inflammation and autoimmune diseases [13]. Given the
non-synchronous changes in Th17 and Treg cells, we
used Th17/Treg to define the relationship between in-
flammation status and regulatory condition of immune
system. Our study demonstrated that in peripheral blood
the Th17/Treg ratio increased in ARDS patients compared
with the healthy controls. The Th17/Treg ratio was also
higher in patients with severe ARDS as compared to those
with mild or moderate ARDS. In addition, a highly signifi-
cant Th17/Treg ratio was found in favor of a proinflamma-
tory Th17-response in non-survivors. Correction of the
Th17/Treg imbalance may help maintain the immune
system in a steady state, and exhibit a therapeutic benefit
for this disease. Indeed, two studies have shown that
losartan and alanyl-glutamine may protect mice from
lipopolysaccharide-induced lung injury by suppressing
Th17 immune responses and modulating the Th17/Treg
balance in favor of Treg cells, respectively [5,12].
Although clinical scores, such as the APACHE II [21],
SOFA [22] and lung injury score [23] have been widely
used in clinical practice to predict outcome in critically
ill patients, the early risk-stratification of these patients
and their prognosis, as well as accurate monitoring of
the effects of clinical treatment, remain a crucial chal-
lenge in critical care. Recently, the new Berlin definitionhas emphasized the notion that ARDS mortality mark-
edly increased with greater severity of hypoxemia as
assessed with PaO2/FiO2 [2]. In the present study, nega-
tive and moderate correlations were observed between
the Th17/Treg ratio and PaO2/FiO2, indicating that the
higher the Th17/Treg ratio, the more adverse the out-
come in ARDS patients. Interestingly, although APA-
CHE II score, SOFA score, and lung injury score all had
significantly positive correlations with the Th17/Treg ra-
tio, the Spearman’s correlation coefficient was the high-
est between the Th17/Treg ratio and lung injury score,
which is more suited to discriminate pulmonary-specific
outcomes [23,27]. Meanwhile, we further found that the
AUC for Th17/Treg ratio for predicting 28-day mortality
in ARDS patients was higher than that for the APACHE
II score, SOFA score, lung injury score or PaO2/FiO2.
However, the AUC for the lung injury score and PaO2/
FiO2 were lower, likely because they are measures of ini-
tial lung injury severity and never intended as a prognos-
tic tool in ARDS. Although the Th17/Treg ratio in
combination with the APACHE II score slightly in-
creased the AUC for predicting 28-day mortality, there
was no difference compared with the Th17/Treg ratio
alone. Moreover, the Th17/Treg ratio, APACHE II score,
and SOFA score were found to be independent predic-
tors of 28-day mortality in ARDS patients, and those pa-
tients with a ratio of Th17/Treg >0.79 had a higher
mortality rate. Taken together, our findings strongly sug-
gest that the Th17/Treg ratio is a potential indicator for
the degree of lung injury and a good index for evaluation
of prognosis in ARDS patients.
Limitations
There were some limitations to this study. First, this is a
single-center study and the sample size was not large,
thus restricting generalizability. However, our data
would be representative enough to observe the alteration
of circulating Th17 and Treg cells and the correlation
between the Th17/Treg ratio with disease severity and
outcome. Moreover, enrolled patients are a mixed popu-
lation of ARDS, including pulmonary and extrapulmon-
ary ARDS. Further studies with larger numbers of
patients are required to confirm our findings. Second,
we just investigated the changes in Th17 and Treg cells
from peripheral blood. Ideally, samples should be taken
either from the alveolar spaces or lung tissue where the
inflammatory events are occurring. However, samples
obtained through bronchoalveolar lavage and/or biopsies
are limited by complexity, especially among critically ill
patients in ICU. More importantly, the alteration of cir-
culating Th17 and Treg cells is present in ARDS, and is
associated with increased disease severity and risk of
mortality, indicating that our method is safe and feasible.
Third, the change in functional immunocompetent cells
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to focus on understanding the effect of the early, inflam-
matory phase of ARDS on clinical outcome. However, the
resolution phase is also important for us to more
comprehensively understand the pathophysiological
process occurring in ARDS. Therefore, further studies
are warranted to longitudinally measure the dynamic
changes in the immunological status of patients during
the whole time course of ARDS. Finally, this study was
not designed to assess the association between the
Th17/Treg ratio and the development of ARDS, and
this will be the focus of our next study.
Conclusions
In summary, Th17 cells and Treg cells increased in the
peripheral blood of patients with early ARDS, and higher
Th17 to Treg cell ratio may be associated with poorer
prognosis. Moreover, strategies designed to restore the
Th17/Treg balance may be a novel and effective thera-
peutic approach in ARDS.
Key messages
 In patients with early ARDS, the peripheral
circulating Th17 and Treg cells and their associated
cytokines increased
 The Th17/Treg ratio towards the Th17 cell subset
contributes to the pathogenesis of ARDS. The
Th17/Treg imbalance may represent a potential
therapeutic target and risk indicator in early ARDS.
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